Abbott Is Up 11% Today. The Real Story Is What Comes Next.

The stock had been left for dead. Down more than 20% year-to-date heading into this morning, Abbott Laboratories (ABT) looked like a casualty of sector rotation, acquisition anxiety, and the kind of slow-burn skepticism that builds when a company spends about $21 billion on a diagnostics deal and then guides earnings lower to absorb the hit.

Then Q2 landed.

The Numbers

Abbott reported adjusted EPS of $1.31, ahead of the $1.28 consensus. Revenue hit $12.59 billion, slightly topping estimates of about $12.5 billion and up 13% year-over-year on a reported basis. The company also raised full-year adjusted EPS guidance to a range of $5.45 to $5.60, up from its prior outlook of $5.38 to $5.58. Full-year comparable sales growth guidance was reaffirmed at 6.5% to 7.5%.

That guidance raise above consensus is the piece that matters most. The market has been pricing in execution risk. Abbott just pushed back against it.

Analyst Targets

TD Cowen: Buy, $115 price target
William Blair: Buy (no specific price target)

Consensus analyst target: approximately $117 (per MarketBeat)

What Actually Drove the Beat

Medical Devices was the engine. The segment generated $5.85 billion in quarterly revenue, up 9% on a reported basis. Inside that, electrophysiology grew in the low double digits, aided by the U.S. launch and continued rollout of Abbott’s Volt PFA system and the expanding international rollout of Volt and the TactiFlex Duo ablation catheter. Rhythm Management, Heart Failure, and Diabetes Care all posted high-single-digit gains.

The continuous glucose monitoring franchise delivered 11% growth in CGM sales on a reported basis during Q2, a return to the double-digit trajectory management had explicitly guided toward after a softer Q1. That’s important. The bears had been pointing to CGM deceleration as evidence the FreeStyle Libre machine was losing steam. This quarter pushes back against that directly.

Diagnostics revenue climbed to $3.09 billion. The Cancer Diagnostics business, anchored by Cologuard following Abbott’s acquisition of Exact Sciences (completed March 23, 2026), posted low-double-digit growth on a comparable basis. That deal was announced at an equity value of approximately $21 billion, and it has been described as dilutive to adjusted EPS through 2027. The market hated it. The first real integration data suggests the logic was sound.

The one soft spot: Nutrition, which fell 3.1% on a reported basis. That segment has been working through strategic pricing actions implemented in the fourth quarter of 2025, and the recovery is still incomplete. Management is not hiding from it.

Slight tangent, but worth noting: Abbott just declared its 410th consecutive quarterly dividend. That is not a typo. The company has paid a dividend every quarter since 1924, and it has raised that dividend for 54 consecutive years. Not many businesses in any sector have that kind of track record. It does not move the stock today. It tells you something about the underlying business that the daily chart cannot.

The Bigger Picture

The investment case for Abbott runs deeper than a single quarter. CEO Robert Ford has pointed to a CGM market that currently reaches roughly 10 to 12 million people globally but should eventually serve 70 to 80 million.

The Exact Sciences deal adds Cologuard, a leading at-home colorectal cancer screening test, and positions Abbott in cancer diagnostics. The company has emphasized growth driven by both new and repeat Cologuard users. That flywheel takes time to show up in numbers. It is starting to.

Bull / Base / Bear

Bull: CGM reaccelerates to double digits, Exact Sciences integration scales faster than modeled, Volt PFA gains share in electrophysiology through H2. Stock approaches analyst consensus near $117.
Base: Medical Devices grows mid-to-high single digits, Nutrition recovers slowly, full-year EPS lands at the high end of $5.60 guidance. Stock grinds toward $105-$110.
Bear: Nutrition drag persists, CGM competition from DexCom intensifies, Exact Sciences dilution runs longer than 2027. The stock gives back today’s gains.

What to Watch Next

Libre Duo: Abbott received CE Mark for the world’s first dual glucose-ketone continuous monitoring sensor and has said it expects U.S. approval in the second half of 2026. That is a product no competitor has. The commercial launch timeline in Europe and the FDA review process are the two milestones to track.

The stock was down more than 20% year-to-date before today’s move. After an 11% session, it is still below where it started 2026. The analyst consensus is roughly $117. That gap is the debate. The question is whether today was the catalyst that starts closing it, or just one quarter in a longer proving period.

That answer lives in the next two earnings reports.

For informational purposes only.